Radiotherapy in early stage Hodgkin's disease.
Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survival and disease-free survival were 95% and 78%, respectively. In this study our goals were to reduce the irradiation volumes, to decrease the number of splenectomies performed at diagnosis, and to utilize radiotherapy alone in these patients. We were able to reduce the irradiation volumes in over 50% and 80% of the patients with disease in the upper torso and subdiaphragm, respectively. Furthermore, this therapeutic approach permitted us to reduce the acute and long-term toxic effects related to splenectomy and combined modality treatment.
Zinzani
P L
PL
Institute of Hematology L. e A. Seràgnoli, University of Bologna, Italy.
Barbieri
E
E
Gherlinzoni
F
F
Frezza
G
G
Mazza
P
P
Pica
A
A
Ammendolia
I
I
Bendandi
M
M
Neri
S
S
Miniaci
G
G
D000293:Adolescent; D000328:Adult; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D012074:Remission Induction; D016879:Salvage Therapy; D013156:Splenectomy; D015996:Survival Rate; D016896:Treatment Outcome
D003037:Cobalt Radioisotopes